Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 3
2001 3
2002 13
2003 12
2004 10
2005 13
2006 7
2007 15
2008 16
2009 13
2010 17
2011 14
2012 11
2013 14
2014 17
2015 11
2016 11
2017 9
2018 9
2019 2
2020 6
2021 12
2022 5
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

226 results

Results by year

Filters applied: . Clear all
Page 1
A randomized double-blind placebo-controlled trial of an inhibitor of plasminogen activator inhibitor-1 (TM5614) in mild to moderate COVID-19.
Hirai T, Asano K, Ito I, Miyazaki Y, Sugiura H, Agirbasli M, Kobayashi S, Kobayashi M, Shimada D, Natsume I, Kawasaki T, Ohba T, Tajiri S, Sakamaki F, Mineshita M, Takihara T, Sekiya K, Tomii K, Tomioka H, Kita H, Nishizaka Y, Fukui M, Miyata T, Harigae H. Hirai T, et al. Among authors: miyata t. Sci Rep. 2024 Jan 2;14(1):165. doi: 10.1038/s41598-023-50445-1. Sci Rep. 2024. PMID: 38168544 Free PMC article. Clinical Trial.
Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel-resistant cutaneous angiosarcoma: Phase II study protocol.
Fujimura T, Yoshino K, Nakamura M, Kato H, Ito T, Maekawa T, Fujisawa Y, Matsushita S, Amagai R, Yamazaki E, Takahashi M, Tamabuchi E, Hashimoto A, Kambayashi Y, Yamazaki N, Miyata T, Asano Y. Fujimura T, et al. Among authors: miyata t. Exp Dermatol. 2024 Jan;33(1):e14976. doi: 10.1111/exd.14976. Epub 2023 Nov 9. Exp Dermatol. 2024. PMID: 37946551
Pyridoxamine prevents increased atherosclerosis by intermittent methylglyoxal spikes in the aortic arches of ApoE-/- mice.
Hanssen NMJ, Tikellis C, Pickering RJ, Dragoljevic D, Lee MKS, Block T, Scheijen JL, Wouters K, Miyata T, Cooper ME, Murphy AJ, Thomas MC, Schalkwijk CG. Hanssen NMJ, et al. Among authors: miyata t. Biomed Pharmacother. 2023 Feb;158:114211. doi: 10.1016/j.biopha.2022.114211. Epub 2023 Jan 3. Biomed Pharmacother. 2023. PMID: 36916437 Free article.
Pyridoxamine reduces methylglyoxal and markers of glycation and endothelial dysfunction, but does not improve insulin sensitivity or vascular function in abdominally obese individuals: A randomized double-blind placebo-controlled trial.
Van den Eynde MDG, Houben AJHM, Scheijen JLJM, Linkens AMA, Niessen PM, Simons N, Hanssen NMJ, Kusters YHAM, Eussen SJMP, Miyata T, Stehouwer CDA, Schalkwijk CG. Van den Eynde MDG, et al. Among authors: miyata t. Diabetes Obes Metab. 2023 May;25(5):1280-1291. doi: 10.1111/dom.14977. Epub 2023 Feb 14. Diabetes Obes Metab. 2023. PMID: 36655410 Clinical Trial.
Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor.
Takahashi N, Kameoka Y, Onizuka M, Onishi Y, Takahashi F, Dan T, Miyata T, Ando K, Harigae H. Takahashi N, et al. Among authors: miyata t. Cancer Med. 2023 Feb;12(4):4250-4258. doi: 10.1002/cam4.5292. Epub 2022 Sep 23. Cancer Med. 2023. PMID: 36151699 Free PMC article.
226 results